Synthesis and biological activity of a gemcitabine phosphoramidate prodrug

Journal of Medicinal Chemistry

Volumn 50, Issue 15, 2007, Pages 3743-3746

  Wu, Weidong ^a,c   Sigmond, Jennifer ^b   Peters, Godefridus J ^b   Borch, Richard F ^a  

^a PURDUE UNIVERSITY   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LaserGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' (2' DEOXY 2',2' DIFLUOROCYTIDYL) 5 NITROFURFURYL N METHYL N (4 CHLOROBUTYL)PHOSPHORAMIDATE; DEOXYCYTIDINE KINASE; DIPYRIDAMOLE; GEMCITABINE; GEMCITABINE 5' MONOPHOSPHATE; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; STRUCTURE ANALYSIS;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CYTIDINE MONOPHOSPHATE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DIPYRIDAMOLE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NUCLEOSIDE TRANSPORT PROTEINS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34547602969     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070269u     Document Type: Article

References (30)

1. Robins, R. K. The potential of nucleoside analogs as inhibitors of retroviruses and tumors. Pharm. Res. 1984, 11-18.
2. Hatse, S.; De Clercq, E.; Balzarini, J. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Biochem. Pharmacol. 1999, 58, 539-555.
3. Jones, R. J.; Bischofberger, N. Minireview: Nucleotide prodrugs. Antiviral Res. 1995, 27, 1-17.
4. Wagner, C. R.; Iyer, V. V.; McIntee, E. J. Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides. Med. Res. Rev. 2000, 20, 417-451.
5. Freel Meyers, C. L.; Hong, L.; Joswig, C.; Borch, R. F. Synthesis and biological activity of novel 5-fluoro-2′-deoxyuridine phosphoramidate prodrugs. J. Med. Chem. 2000, 43, 4313-4318.
6. Freel Meyers, C. L.; Borch, R. F. Activation mechanisms of nucleoside phosphoramidate prodrugs. J. Med. Chem. 2000, 43, 4319-4327.
7. Tobias, S. C.; Borch, R. F. Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs. J. Med. Chem. 2001, 44, 4475-4480.
8. Tobias, S. C.; Borch, R. F. Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol. Pharmaceutics 2004, 1, 112-116.
9. Hertel, L. W.; Boder, G. B.; Kroin, J. S.; Rinzel, S. M.; Poore, G. A.; Todd, G. C.; Grindey, G. B. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. 1990, 50, 4417-4422.
10. Plunkett, W.; Huang, P.; Gandhi, V. Preclinical characteristics of gemcitabine. Anti-Cancer Drugs 1995, 6 Suppl. 6, 7-13.
11. Plunkett, W.; Huang, P.; Xu, Y. Z.; Heinemann, V.; Grunewald, R.; Gandhi, V. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin. Oncol. 1995, 22, 3-10.
12. van Moorsel, C. J.; Peters, G. J.; Pinedo, H. M. Gemcitabine: Future prospects of single-agent and combination studies. Oncologist 1997, 2, 127-134.
13. Kroep, J. R.; Peters, G. J.; Nagourney, R. A. Clinical activity of gemcitabine as a single agent and in combination. In Cancer Drug Discovery and Development: Deoxynucleoside Analogs in Cancer Therapy; Peters, G. J., Ed.; Humana Press, Inc.: Totowa, NJ, 2006; pp 253-287.
14. Heinemann, V.; Hertel, L. W.; Grindey, G. B.; Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res. 1988, 48, 4024-4031.
15. Heinemann, V.; Schulz, L.; Issels, R. D.; Wilmanns, W. Regulation of deoxycytidine kinase by deoxycytidine and deoxycytidine 5′-triphosphate in whole leukemia and tumor cells. Adv. Exp. Med. Biol. 1998, 431, 249-253.
16. van der Wilt, C. L.; Kroep, J. R.; Bergman, A. M.; Loves, W. J.; Alvarez, E.; Talianidis, I.; Eriksson, S.; van Groeningen, C. J.; Pinedo, H. M.; Peters, G. J. The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv. Exp. Med. Biol. 2000, 486, 287-290.
17. Bergman, A. M.; Pinedo, H. M.; Peters, G. J. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist. Updates 2002, 5, 19-33.
18. Gregoire, V.; Rosier, J. F.; De Bast, M.; Bruniaux, M.; De Coster, B.; Octave-Prignot, M.; Scalliet, P. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro. Radiother. Oncol. 2002, 63, 329-338.
19. Griffith, D. A.; Jarvis, S. M. Nucleoside and nucleobase transport systems of mammalian cells. Biochim. Biophys. Acta 1996, 1286, 153-181.
20. +-dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells. J. Pharmacol. Exp. Ther. 1998, 286, 1333-1340.
21. Jansen, W. J.; Pinedo, H. M.; van der Wilt, C. L.; Feller, N.; Bamberger, U.; Boven, E. The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts. Eur. J. Cancer 1995, 31A, 2313-2319.
22. Hayakawa, Y.; Kato, H.; Uchiyama, M.; Kajino, H.; Noyori, R. Allyloxycarbonyl group: A versatile blocking group for nucleoside synthesis. J. Org. Chem. 1986, 51, 2400-2402.
23. Heidenhain, S. B.; Hayakawa, Y. A convenient way to N- allyloxycarbonyl protected adenosine and cytidine derivatives. Synlett 1998, 853-854.
24. Wu, W.; Freel Meyers, C. L.; Borch, R. F. A novel method for the preparation of nucleoside triphosphates from activated nucleoside phosphoramidates. Org. Lett. 2004, 6, 2257-2260.
25. Meyers, C. L.; Borch, R. F. A novel method for the preparation of nucleoside diphosphates. Org. Lett. 2001, 3, 3765-3768.
26. Visser, F.; Vickers, M. F.; Ng, A. M.; Baldwin, S. A.; Young, J. D.; Cass, C. E. Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. J. Biol. Chem. 2002, 277, 395-401.
27. Ruiz van Haperen, V. W.; Veerman, G.; Eriksson, S.; Boven, E.; Stegmann, A. P.; Hermsen, M.; Vermorken, J. B.; Pinedo, H. M.; Peters, G. J. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine- resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res. 1994, 54, 4138-4143.
28. Keepers, Y. P.; Pizao, P. E.; Peters, G. J.; van Ark-Otte, J.; Winograd, B.; Pinedo, H. M. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur. J. Cancer 1991, 27, 897-900.
29. Rots, M. G.; Pieters, R.; Kaspers, G. J.; van Zantwijk, C. H.; Noordhuis, P.; Mauritz, R.; Veerman, A. J.; Jansen, G.; Peters, G. J. Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay. Blood 1999, 93, 1067-1074.
30. Kroep, J. R.; Loves, W. J.; van der Wilt, C. L.; Alvarez, E.; Talianidis, I.; Boven, E.; Braakhuis, B. J.; van Groeningen, C. J.; Pinedo, H. M.; Peters, G. J. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther. 2002, 1, 371-376.